Peginterferon alfa-2b and ribavirin in thalassaemia/chronic hepatitis C virus-co-infected non-responder to standard interferon-based therapy

Hamidah Alias, C. R. Thambidorai, A. Rahman A. Jamal

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We describe a patient with HbE-beta thalassaemia and chronic hepatitis C virus infection (genotype 1a) who was treated successfully with peginterferon alfa-2b and ribavirin, following failure to respond to standard interferon and ribavirin therapy. She had sustained virological response for nearly 24 months after completing peginterferon alfa-2b and ribavirin therapy. Transfusion requirements were significantly increased during combination therapy due to ribavirin-induced haemolysis. The adverse effects of interferon were well tolerated. Combination therapy with peginterferon alfa-2b and ribavirin maybe a feasible treatment option for a subset of thalassaemia/HCV infected non-responders to standard interferon-based therapy.

Original languageEnglish
Pages (from-to)517-519
Number of pages3
JournalMedical Journal of Malaysia
Volume60
Issue number4
Publication statusPublished - 2005

Fingerprint

Thalassemia
Ribavirin
Chronic Hepatitis C
Hepacivirus
Interferons
Therapeutics
beta-Thalassemia
Virus Diseases
Hemolysis
peginterferon alfa-2b
Genotype

Keywords

  • Blood transfusion
  • Hepatitis C virus
  • Peginterferon
  • Ribavirin
  • Thalassaemia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{b4de8c13953f4db89b1afe99d27384c1,
title = "Peginterferon alfa-2b and ribavirin in thalassaemia/chronic hepatitis C virus-co-infected non-responder to standard interferon-based therapy",
abstract = "We describe a patient with HbE-beta thalassaemia and chronic hepatitis C virus infection (genotype 1a) who was treated successfully with peginterferon alfa-2b and ribavirin, following failure to respond to standard interferon and ribavirin therapy. She had sustained virological response for nearly 24 months after completing peginterferon alfa-2b and ribavirin therapy. Transfusion requirements were significantly increased during combination therapy due to ribavirin-induced haemolysis. The adverse effects of interferon were well tolerated. Combination therapy with peginterferon alfa-2b and ribavirin maybe a feasible treatment option for a subset of thalassaemia/HCV infected non-responders to standard interferon-based therapy.",
keywords = "Blood transfusion, Hepatitis C virus, Peginterferon, Ribavirin, Thalassaemia",
author = "Hamidah Alias and Thambidorai, {C. R.} and {A. Jamal}, {A. Rahman}",
year = "2005",
language = "English",
volume = "60",
pages = "517--519",
journal = "Medical Journal of Malaysia",
issn = "0300-5283",
publisher = "Malaysian Medical Association",
number = "4",

}

TY - JOUR

T1 - Peginterferon alfa-2b and ribavirin in thalassaemia/chronic hepatitis C virus-co-infected non-responder to standard interferon-based therapy

AU - Alias, Hamidah

AU - Thambidorai, C. R.

AU - A. Jamal, A. Rahman

PY - 2005

Y1 - 2005

N2 - We describe a patient with HbE-beta thalassaemia and chronic hepatitis C virus infection (genotype 1a) who was treated successfully with peginterferon alfa-2b and ribavirin, following failure to respond to standard interferon and ribavirin therapy. She had sustained virological response for nearly 24 months after completing peginterferon alfa-2b and ribavirin therapy. Transfusion requirements were significantly increased during combination therapy due to ribavirin-induced haemolysis. The adverse effects of interferon were well tolerated. Combination therapy with peginterferon alfa-2b and ribavirin maybe a feasible treatment option for a subset of thalassaemia/HCV infected non-responders to standard interferon-based therapy.

AB - We describe a patient with HbE-beta thalassaemia and chronic hepatitis C virus infection (genotype 1a) who was treated successfully with peginterferon alfa-2b and ribavirin, following failure to respond to standard interferon and ribavirin therapy. She had sustained virological response for nearly 24 months after completing peginterferon alfa-2b and ribavirin therapy. Transfusion requirements were significantly increased during combination therapy due to ribavirin-induced haemolysis. The adverse effects of interferon were well tolerated. Combination therapy with peginterferon alfa-2b and ribavirin maybe a feasible treatment option for a subset of thalassaemia/HCV infected non-responders to standard interferon-based therapy.

KW - Blood transfusion

KW - Hepatitis C virus

KW - Peginterferon

KW - Ribavirin

KW - Thalassaemia

UR - http://www.scopus.com/inward/record.url?scp=33646715601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646715601&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 517

EP - 519

JO - Medical Journal of Malaysia

JF - Medical Journal of Malaysia

SN - 0300-5283

IS - 4

ER -